Erratum: Subgroup analysis of the AFTER I-O study: A retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma (Japanese Journal of Clinical Oncology (2021) DOI: 10.1093/jjco/hyab114)

Yoshihiko Tomita, Go Kimura, Satoshi Fukasawa, Kazuyuki Numakura, Yutaka Sugiyama, Kazutoshi Yamana, Sei Naito, Hirokazu Kaneko, Yohei Tajima, Mototsugu Oya

研究成果: Comment/debate査読

1 被引用数 (Scopus)

抄録

In the originally published article there were errors in the legends to figures 3 and 4. Figure 3 should read: "Figure 3. PFS2 of nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) PFS2 of NIVO, stratified by TT regimens after NIVO, sunitinib, or axitinib. (b) PFS2 of NIVO+IPI, stratified by TT regimens after NIVO+IPI, sunitinib, or axitinib, IMDC all risks." instead of: "Figure 3.OS from first-line therapy of patients treated with nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) OS from first-linetherapy of patients treated with NIVO, stratified by TT regimens after NIVO, sunitinib or axitinib. (b) OS from first-line therapy of patients treated with NIVO+IPI,stratified by TT regimens after NIVO+IPI, sunitinib or axitinib, IMDC all risks.". Figure 4 should read: "Figure 4. OS from first-line therapy of patients treated with nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) OS from first-linetherapy of patients treatedwithNIVO, stratified by TT regimens afterNIVO, sunitinib or axitinib. (b) OS from first-line therapy of patients treated with NIVO+IPI,stratified by TT regimens after NIVO+IPI, sunitinib or axitinib, IMDC all risks." instead of: "Figure 4. PFS2 of nivolumab (NIVO) or nivolumab and ipilimumab combination therapy (NIVO+IPI). (a) PFS2 of NIVO, stratified by TT regimens after NIVO, sunitinib, or axitinib. (b) PFS2 of NIVO+IPI, stratified by TT regimens after NIVO+IPI, sunitinib, or axitinib, IMDC all risks.". These errors have now been corrected online.

本文言語English
ページ(範囲)1770
ページ数1
ジャーナルJapanese journal of clinical oncology
51
12
DOI
出版ステータスPublished - 2021 12月 1

ASJC Scopus subject areas

  • 腫瘍学
  • 放射線学、核医学およびイメージング
  • 癌研究

フィンガープリント

「Erratum: Subgroup analysis of the AFTER I-O study: A retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma (Japanese Journal of Clinical Oncology (2021) DOI: 10.1093/jjco/hyab114)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル